Week in Review: Bain Capital Enters China Healthcare Market with $150 Million Deal

Bain Capital paid $150 million for a majority stake in Asia Pacific Medical Group, a collection of five hospitals and several clinics in China and southeast Asia; Chi-Med completed a $101.5 million initial US offering, pricing the shares about 17% below expectations; Human Health Holdings, a Hong Kong health clinic operator, is planning a $13 million IPO; Hong Kong's Prenetics raised $10 million in a Series A funding for its DNA clinical pharmacogenomics tests; SK Telecom of Korea will bring Cleveland HeartLab's cardiovascular diagnostics to China; Sinopharm obtained exclusive China rights to a wound healing technology developed by Avita Medical of Australia; Bird Rock Bio, a San Diego-China biopharma, reported positive data from two clinical studies of its low-cost rheumatoid arthritis drug candidate; Quark Pharma of the US and Israel began a China arm of a global Phase II/III trial for its siRNA blindness treatment; China's Asieris Pharma presented positive preliminary results from an ongoing Phase II trial of its bladder cancer drug; and the 8th annual ChinaBio® Partnering Forum 2016 life science partnering event will return to Suzhou, China, May 18–19. More details.... Stock Symbols: (NSDQ: HCM; AIM: HCM) (NYSE: SKM, KSE: 017670) (HK: 1099) (ASX: AVH; OTCQX: AVMXY) Share this with colleagues: // //